ClinicalTrials.gg
CompletedNCT04378153SIMPLIFYUpdated Dec 4, 2024Results posted

Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy

An observational study in Cystic Fibrosis, sponsored by Nicole Hamblett. Completed at 80 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by Nicole Hamblett · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
987
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Enrollment
16th of 193
987 · median 80
Started
2020
with 33 others
Observational
194 of 717
41 open now
Registered
540th of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 16th largest by enrollment of the 193 observational ones that give a count, is one of 34 that started in 2020, is one of 194 observational ones, and was the 540th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

80 more — sign in →

All 85 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

Despite the increasingly common use of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies in treating CF, it is still largely unknown whether or not other chronic therapies can be safely stopped. The SIMPLIFY study is being done to test whether or not it is safe to stop taking inhaled hypertonic saline or Pulmozyme® (dornase alfa) in those people that are also taking Trikafta™.

Trikafta (elexacaftor/tezacaftor/ivacaftor) is a combination CFTR modulator therapy that was approved by the Food and Drug Administration for people with CF who have at least one F508del mutation. The three drugs that make up Trikafta work together to allow many more chloride ions to move into and out of the cells, improving the balance of salt and water in the lungs. These changes result in better clearance of mucus from the lungs and improvements in lung function.

Inhaled hypertonic saline and Pulmozyme (dornase alfa) also improve clearance of mucus from the lungs to support lung function and have been available to people with CF for many years. Both therapies are considered to be relatively burdensome and it is not known whether either therapy can improve or maintain lung function above what is already gained through Trikafta use.

The goal of the SIMPLIFY study is to get information about whether or not it is safe to stop either inhaled hypertonic saline or Pulmozyme (dornase alfa) by testing if there is a change in lung function in subjects with cystic fibrosis (CF) who are assigned to stop their chronic medication (either hypertonic saline or Pulmozyme) as compared to those who are assigned to keep taking their medication while continuing to take Trikafta.

Read the detailed description

SIMPLIFY-IP-19 is a master protocol is designed to evaluate the independent effects of discontinuing hypertonic saline or dornase alfa in people with cystic fibrosis (CF) age 12 and older currently taking the highly effective modulator elexacaftor/tezacaftor/ivacaftor (ETI). The hypertonic saline and dornase alfa sub studies are identical open label two-arm randomized non-inferiority trials consisting of a 2-week run-in period, randomization to continue or discontinue hypertonic saline or dornase alfa, followed by a 6-week study period. Subjects taking only hypertonic saline (HS) or dornase alfa at trial entry will be randomized 1:1 to either continue or discontinue the applicable therapy (i.e. HS or dornase alfa). Subjects taking both hypertonic saline and dornase alfa at study entry will be randomized to participate in either the hypertonic saline or dornase alfa and will be randomized (1:1) to continue or discontinue the applicable therapy (i.e. HS or dornase alfa). After completion of the first study, eligible subjects may subsequently enroll in the alternative study.

This clinicalrials.gov registration, NCT04378153, summarizes the 2-week run-in and adherence period prior to participant enrollment in either the Hypertonic Saline or Dornase Alfa sub studies.

Two additional clincialtrials.gov records document the sub study specific enrollment and outcome measures.

Hypertonic Saline Study Record

  • NCT06350461
  • Brief Title: Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study (SIMPLIFY-HS)

Dornase Alfa Study Record

  • NCT06350474
  • Brief Title: Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study (SIMPLIFY-DN)
03

Conditions studied

  • Cystic Fibrosis

Browse trials for

Keywords

  • Cystic Fibrosis
  • CF
  • Withdrawal
  • Trikafta
  • hypertonic saline
  • dornase alfa
  • pulmozyme
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with Cystic Fibrosis using either hypertonic saline or dornase alfa chronically (see eligibility criteria).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of CF.
  • Age ≥ 12 years at the Screening Visit.
  • (FEV1) ≥ 70 % predicted at the Screening Visit if \< 18 years old, and ≥ 60 % predicted at Screening Visit if ≥ 18 years old.
  • Clinically stable with no significant changes in health status within the 7 days prior to and including the Screening Visit.
  • Current treatment with elexacaftor/tezacaftor/ivacaftor (ETI) for at least the 90 days prior to and including the Screening Visit and willing to continue daily use for the duration of the study.
  • Currently taking hypertonic saline (at least 3%) and/or dornase alfa for at least the 90 days prior to and including the Screening Visit and willing to continue daily use for the 2-week screening period.

Exclusion criteria

Exclusion Criteria:

  • Active smoking or vaping.
  • Use of an drug within 28 days prior to and including the Screening Visit.
  • Changes to chronic therapy (e.g., ibuprofen, azithromycin, inhaled tobramycin, aztreonam lysine) within 28 days prior to and including the Screening Visit. This includes new airway clearance routines.
  • Acute use of antibiotics (oral, inhaled or IV) or acute use of systemic for respiratory tract symptoms within 7 days prior to and including the Screening Visit.
  • Chronic use of systemic corticosteroids at a dose equivalent to ≥ 10mg per day of prednisone within 28 days prior to and including the Screening Visit.
  • Antibiotic treatment for nontuberculous mycobacteria (NTM) within 28 days prior to and including the Screening Visit.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
987 participants (actual)
Patient registry
No

Groups and cohorts

  • Master Study Run-in

    Participants enrolled in the run-in phase of the master protocol.

06

What researchers measure

Primary outcomes

  1. Number of Participants Eligible to be Assessed for Sub-study Enrollment

    The number of participants completing the run-in period of the study and not meeting any of the exclusion criteria during the run-in period.

    Time frame: 2-week run-in period

07

Results

Posted Sep 23, 2024
Limitations and caveats
Adverse events were not collected as part of the run-in phase of the study.

Participant flow

Participant flow — Overall Study
MilestoneMaster Study Run-in
Started987
Completed903
Not completed84

Outcome measures

PrimaryNumber of Participants Eligible to be Assessed for Sub-study Enrollment

The number of participants completing the run-in period of the study and not meeting any of the exclusion criteria during the run-in period.

Time frame:
2-week run-in period
Reported as:
Count of participants · Participants
Number of Participants Eligible to be Assessed for Sub-study Enrollment
ParticipantsMaster Study Run-in
Number of Participants Eligible to be Assessed for Sub-study Enrollment870
Statistical analysis
  • Master Study Run-in · Fisher Exact · p = 0.1215 · Difference in % participants: 2.17 · 95% CI -0.7 to 5.7Confidence interval calculated using the Newcombe-Wilson method without continuity correction. Direction of difference is Discontinue - Continue.

Adverse events

Collected over Adverse events were not collected during the run-in phase of the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Master Study Run-in———

Baseline characteristics

Age, Continuous
Age, Continuous(years)Master Study Run-in
Mean22.1 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Master Study Run-in
Female480
Male507
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Master Study Run-in
Hispanic or Latino67
Not Hispanic or Latino920
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Master Study Run-in
Race — White950
Race — Black or African American12
Race — Asian2
Race — American Indian or Alaskan Native1
Race — Native Hawaiian or Other Pacific Islander0
Race — Other, More than One Race, or Unknown/Not Reported22
FEV1 (% Predicted)
FEV1 (% Predicted)(Percent Predicted)Master Study Run-in
Mean96.7 ± 16.8
Current Medication Use
Current Medication Use(Participants)Master Study Run-in
Dornase Alfa Only232
Hypertonic Saline Only65
Both Hypertonic Saline and Dornase Alfa690
08

Study locations

80 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Providence Alaska Medical Center
    Anchorage, Alaska 99508, United States
  • Tucson Cystic Fibrosis Center
    Tucson, Arizona 85724, United States
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Miller Children's and Women's Hospital Long Beach
    Long Beach, California 90806, United States
  • CHOC Children's Hospital
    Orange, California 92868, United States
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
  • Rady Children's Hospital and Health Center at the University of California San Diego
    San Diego, California 92123, United States
  • University of California, San Francisco - Adult Center
    San Francisco, California 94143, United States
  • University of California, San Francisco - Peds Center
    San Francisco, California 94158, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Nemours Children's Clinic
    Jacksonville, Florida 32207, United States
  • Central Florida Pulmonary Group
    Orlando, Florida 32803, United States
  • The Nemours Children's Clinic - Orlando
    Orlando, Florida 32827, United States
  • Nemours Children's Clinic - Pensacola
    Pensacola, Florida 32514, United States
  • All Children's Hospital
    Saint Petersburg, Florida 33701, United States
  • Tampa General Hospital
    Tampa, Florida 33606, United States
  • Emory University
    Atlanta, Georgia 30327, United States
  • Saint Luke's Cystic Fibrosis Center of Idaho
    Boise, Idaho 83702, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • OSF Saint Francis Medical Center
    Peoria, Illinois 61637, United States
  • Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Kentucky
    Lexington, Kentucky 40506, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Tulane University
    Metairie, Louisiana 70001, United States
  • Maine Medical Partners Pediatric Specialty Care
    Portland, Maine 04102, United States
  • John Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Boston Children's Hospital, Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • University of Michigan, Michigan Medicine
    Ann Arbor, Michigan 48109, United States
  • Wayne State University Harper University Hospital
    Detroit, Michigan 48201, United States
  • Helen DeVos Children's Hospital
    Grand Rapids, Michigan 49503, United States
  • Children's Hospitals and Clinics of Minnesota
    Minneapolis, Minnesota 55404, United States
  • The Minnesota Cystic Fibrosis Center
    Minneapolis, Minnesota 55455, United States
  • Children's Mercy Kansas City
    Kansas City, Missouri 64108, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Billings Clinic
    Billings, Montana 59101, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Monmouth Medical Center
    Eatontown, New Jersey 07724, United States
  • Morristown Medical Center
    Morristown, New Jersey 07960, United States
  • Rutgers - Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08903, United States
  • Cohen Children's Medical Center of New York
    Lake Success, New York 11042, United States
  • Beth Israel Medical Center
    New York, New York 10003, United States
  • Columbia University Cystic Fibrosis Program
    New York, New York 10032, United States
  • University of Rochester Medical Center Strong Memorial
    Rochester, New York 14642, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • New York Medical College at Westchester Medical Center
    Valhalla, New York 10595, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Wake Forest University Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Children's Hospital Medical Center of Akron
    Akron, Ohio 44308, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44146, United States
  • Cleveland Clinic Cystic Fibrosis Program
    Cleveland, Ohio 44195, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Dayton Children's Hospital
    Dayton, Ohio 45404, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
  • Hershey Medical Center Pennsylvania State University
    Hershey, Pennsylvania 17033, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15224, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Dell Children's Medical Center of Central Texas
    Austin, Texas 78723, United States
  • University of Texas Southwestern / Children's Health
    Dallas, Texas 75207, United States
  • University of Texas Southwestern
    Dallas, Texas 75390, United States
  • Cook Children's Medical Center
    Fort Worth, Texas 76104, United States
  • University of Texas Health Center at Tyler
    Tyler, Texas 75708, United States
  • Primary Children's Cystic Fibrosis Center
    Salt Lake City, Utah 84113, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23219, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • Providence Medical Group, Cystic Fibrosis Center
    Spokane, Washington 99204, United States
  • West Virginia University - Morgantown
    Morgantown, West Virginia 26507, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • Children's Hospital of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Froedtert & Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA, Sawicki GS, Odem-Davis K, Young JK, Rosenbluth D, Taylor-Cousar JL, Goss CH, Retsch-Bogart G, Clancy JP, Genatossio A, O'Sullivan BP, Berlinski A, Millard SL, Omlor G, Wyatt CA, Moffett K, Nichols DP, Gifford AH; SIMPLIFY Study Group. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Lancet Respir Med. 2023 Apr;11(4):329-340. doi: 10.1016/S2213-2600(22)00434-9. Epub 2022 Nov 4. PubMed 36343646 ↗
  • Yang C, Montgomery M. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2021 Mar 18;3(3):CD001127. doi: 10.1002/14651858.CD001127.pub5. PubMed 33735508 ↗
  • Mayer-Hamblett N, Nichols DP, Odem-Davis K, Riekert KA, Sawicki GS, Donaldson SH, Ratjen F, Konstan MW, Simon N, Rosenbluth DB, Retsch-Bogart G, Clancy JP, VanDalfsen JM, Buckingham R, Gifford AH. Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design. Ann Am Thorac Soc. 2021 Aug;18(8):1397-1405. doi: 10.1513/AnnalsATS.202010-1336SD. PubMed 33465316 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Jul 2022, 22 months.

Results were first posted in Sep 2024, 2 years 2 months after primary completion.

Of 228 non-industry observational studies under Cystic Fibrosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 89. This study's 22 months is below that.

Counting every sponsor, half of 243 studies reached it within 41 months; a quarter within 19 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2020
First posted
May 7, 2020
StartActual
Aug 25, 2020
Primary completionActual
Jul 11, 2022
CompletionActual
Jul 11, 2022
Results first posted
Sep 23, 2024
Last update
Dec 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04378153
Lead sponsor
Nicole Hamblett
Collaborators
Cystic Fibrosis Foundation, Dartmouth-Hitchcock Medical Center, University of Washington
Responsible party
Nicole Hamblett (Professor of Pediatrics, Division of Pulmonary and Sleep Medicine, University of Washington School of Medicine Adjunct Professor, Biostatistics, University of Washington School of Medicine Co-Executive Director, Cystic Fibrosis Therapeutics Development, Seattle Children's Hospital) — Sponsor-investigator
First posted
May 7, 2020
Start date
Aug 25, 2020
Primary completion
Jul 11, 2022
Completion
Jul 11, 2022
Results posted
Sep 23, 2024
Last update
Dec 4, 2024

Study contacts

Nicole Mayer-Hamblett, PhD
principal investigator · University of Washington/Seattle Children's
Alex Gifford, MD, FCCP
principal investigator · Dartmouth-Hitchcock Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion